Applying in silico, in vitro and in vivo models to mitigate clinical failure.
As demonstrated by Vioxx and Exanta, failing to identify adverse effects of new drugs can be financially devestating. With budget cuts hitting the R&D field hard, ensuring candidate compounds are safe is even more important to reduce late stage attrition and product withdrawals.
But how do we cost-effectively develop and implement these in silico, in vitro and in vivo methods as early in drug discovery and development as possible? How do we demonstrate the validation of these methods?
Network with these industry leaders and learn how to:
Implement the latest developments in predictive toxicology with crucial insight on computational tools from Bayer and the FDA
Cost-effectively integrate cellular assays into established screening programmes with case studies for hepatotoxicity with UCB
Assess the in vitro - in vivo correlation from clinical data for cardiotoxicity with Gilead
Artists / Speakers: Pfizer Neusentis, Bayer AG, Janssen Pharmaceuticals (J&J), UCB SA, GLAXOSMITHKLINE, Novartis Pharma AG, Roche AG, Merck Serono, Lundbeck A/S, F. Hoffman La Roche, Gilead Sciences